Gsk Share Discussion Threads

[vas007] 11/11/2022 10:11

Ceo like this and Philip Jansen should be accountable for the poor share price.

[palfrey man] 11/11/2022 10:00

Look at the management, a perfect example of the Peter principle.

[rikky72] 11/11/2022 09:57

Problem is that oncology, which was supposed to be the new centre piece of the company under Hal, appears to be unravelling..

[spoole5] 11/11/2022 09:46

Worst demerger in history. Emma is a reverse midas

[bilster1] 11/11/2022 09:38

I am really considering why I'm invested in this company !

[spoole5] 11/11/2022 09:23

Part of ceo remuneration should be based on share price performance relative to the appropriate index.

[alibizzle] 11/11/2022 09:18

Share price collapsed again

[tradermichael] 11/11/2022 08:09

Good news:
After the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn Beta, the vaccine has been approved by the European Commission as a booster for the prevention of COVID-19 in adults 18 years of age and older. Next-generation COVID-19 vaccines are based on a variant-adapted approach, using a strain other than the parental strain of SARS-CoV-2 (D614 strain). The vaccine is based on the Beta variant antigen and includes GSK's pandemic adjuvant. The vaccine is indicated as a booster for active immunisation against SARS-CoV-2 in adults who have previously received a mRNA or adenoviral COVID-19 vaccine. Shipments of the vaccine are ready to be distributed to European countries as per the Advance Purchase Agreements.

Thomas Triomphe, Executive Vice President, Sanofi Vaccines: "Today's approval validates our research in developing a novel solution for the COVID-19 pandemic. As we're ready to start first shipments, VidPrevtyn Beta will be an important new option to protect populations against multiple strains of COVID-19."

[vas007] 11/11/2022 08:05

Could you enlighten us ,txns

[spoole5] 11/11/2022 08:03

The bad news keeps coming!

[netcurtains] 09/11/2022 12:52

Its certainly done the share price some good!

[tradermichael] 09/11/2022 12:25

How about this, then??

GSK has presented positive mid-stage trial data for a potential new blockbuster liver drug only a day after suffering a setback with an important cancer treatment.

The British drugs company said the results of a study of bepirovirsen for the treatment of chronic hepatitis B could help to lead to a breakthrough in finding a “functional cure” for what researchers called an “ancient disease”.

[bothdavis] 09/11/2022 12:23

So.....are the figures correct....because if so....whats the beef?

Surely all drug manufaturers have thjis problem....products don't perform as per, so they have to either junk it at a huge cost or tweak it.....will always be so...?

[tradermichael] 08/11/2022 10:11

GSK now has:
8 new products at Registration
18 new entities at Phase III
21 new entities at Phase II
35 new entities at Phase I

[garycook] 08/11/2022 00:53

TM,Thanks, Seeing we will receive 67p for 2022,then adjusted for HLN spin off 61.25p.2023 agreed 56.25p

[alphorn] 07/11/2022 16:18

The main issue is of course incremental sales. Big pharma has to run like crazy just to stand still as drugs come off IPP. To give a balanced picture both sides should be presented. (No current position).

[dr biotech] 07/11/2022 16:01

Yep. To put things in perspective this article from last year shows the expected sales of blenrep and other "new" GSK drugs. Doesn't mean its a dead product as it does have some efficacy, but its more likely to be used when other therapy fails, so sales will be much smaller.

hxxps://www.evaluate.com/vantage/articles/news/corporate-strategy/new-glaxo-its-all-about-late-stage-assets

[netcurtains] 07/11/2022 15:56

So what percentage of revenue/profits etc was this new drug meant to achieve for SSK?
Eg what percentage should the share price fall due to the "failure" of this drug?

Has anyone got a very rough idea?

[spoole5] 07/11/2022 15:53

Always something with this company

[dr biotech] 07/11/2022 14:21

Blenrep was one of the key drivers for revenues going forward. For it to fail the trial is a significant blow.

[tradermichael] 07/11/2022 13:34

Gary, for the next two GSK financial years,

2022: It expects to pay a total dividend for the year of 61.25p per new share.

2023: It expects to declare a dividend of 56.25p per share for 2023.

[tradermichael] 07/11/2022 13:08

RSharman and alexis, et al., almost certainly due to disappointing initial results. However, Glaxo said data from the trial will be shared with health authorities and discussions are currently ongoing, with additional trials of Blenrep continuing as planned as follows:.

GSK said additional trials within the DREAMM clinical trial programme will continue. They are designed to demonstrate the benefit of Blenrep in combination treatment with novel therapies and standard-of-care treatments in earlier lines of therapy.

The company expects data from the DREAMM-7 and DREAMM-8 phase III trials in the first half of 2023. These are combination treatment trials, designed to test the efficacy of Blenrep in combination with bortezomib and dexamethasone, and pomalidomide and dexamethasone, respectively.

[netcurtains] 07/11/2022 13:03

I'm assuming it's the drug trial. It doesn't take much to knock a thinly traded stock downwards.

I guess once fall stops, its a buying opportunity, provided no more news. I'll wait to see what the press says.